{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:37:34Z","timestamp":1784752654934,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clml.2012.12.011","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T15:04:40Z","timestamp":1359039880000},"page":"253-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Jean","family":"Yared","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzefa","family":"Bahrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Auerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.12.011_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.12.011_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S1548-5315(11)70416-8","article-title":"Experience with maintenance rituximab after chemotherapy in patients with low-grade lymphoma","volume":"7","author":"Ayoola","year":"2010","journal-title":"Community Oncology"},{"key":"10.1016\/j.clml.2012.12.011_bib3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib5","first-page":"6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a)","volume":"116","author":"Ardeshna","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.12.011_bib8","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.12.011_bib9","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2012.12.011_bib11","first-page":"2714","volume":"118","author":"Schneider","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib12","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.011_bib13","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib14","first-page":"3420","article-title":"Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT)","volume":"110","author":"Kahl","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib15","first-page":"LBA-6","article-title":"Results of Eastern Cooperative Oncology Group Protocol E4402","volume":"118","author":"Kahl","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib16","first-page":"1802","article-title":"Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03","volume":"116","author":"Taverna","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0129","article-title":"Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice","volume":"8","author":"Rummel","year":"2010","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2012.12.011_bib18","first-page":"3945","article-title":"Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: updated results from the phase IIIb MAXIMA study","volume":"116","author":"Foa","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.12.011_bib20","first-page":"3833","article-title":"Cost effectiveness analysis of rituximab maintenance in patients with untreated high tumour burden follicular lymphoma after response to immunochemotherapy: a UK national healthcare services perspective","volume":"116","author":"Papadakis","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.12.011_bib21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2012.12.011_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:35Z","timestamp":1761870215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2152265012002972"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}